Pasar al contenido principal

ESTUDIO CLINICO-PATOLOGICO Y MOLECULAR DEL CANCER DE TIROIDES FAMILIAR NO MEDULAR

PI19/01316

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (IDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

  • Rodrigues, Joana S.
  • Chenlo, Miguel
  • Bravo, Susana B.
  • Pérez-Romero, Sihara
  • Suarez-Fariña, Maria
  • Sobrino, Tomás
  • Sanz-Pamplona, Rebeca
  • González-Prieto, Román
  • Blanco Freire, Manuel Narciso
  • Nogueiras, Ruben
  • López, Miguel
  • Fugazzola, Laura
  • Cameselle-Teijeiro, José Manuel
  • Álvarez, Clara V.
The E3 SUMO ligase PIAS2 is expressed at high levels in differentiated papillary thyroid carcinomas but at low levels in anaplastic thyroid carcinomas (ATC), an undifferentiated cancer with high mortality. We show here that depletion of the PIAS2 beta isoform with a transcribed double-stranded RNA-directed RNA interference (PIAS2b-dsRNAi) specifically inhibits growth of ATC cell lines and patient primary cultures in vitro and of orthotopic patient-derived xenografts (oPDX) in vivo. Critically, PIAS2b-dsRNAi does not affect growth of normal or non-anaplastic thyroid tumor cultures (differentiated carcinoma, benign lesions) or cell lines. PIAS2b-dsRNAi also has an anti-cancer effect on other anaplastic human cancers (pancreas, lung, and gastric). Mechanistically, PIAS2b is required for proper mitotic spindle and centrosome assembly, and it is a dosage-sensitive protein in ATC. PIAS2b depletion promotes mitotic catastrophe at prophase. High-throughput proteomics reveals the proteasome (PSMC5) and spindle cytoskeleton (TUBB3) to be direct targets of PIAS2b SUMOylation at mitotic initiation. These results identify PIAS2b-dsRNAi as a promising therapy for ATC and other aggressive anaplastic carcinomas., This work was supported by Agencia Estatal de Investigación (AEI, Spain), co-funded by the European Union, projects’ codes BFU2013-46109-R, BFU2016-76973-R, PID2019-110437RB-I00, PDC2021-121621-I00 and PID2022-140149OB-I00 to C.V.A. This work has received financial support from the Xunta de Galicia (Centro singular de investigación de Galicia accreditation 2019-2022) and the European Union (European Regional Development Fund - ERDF). J.M.C.-T. is supported by grant no. ISCIII-PI23/00722, and PI19/01316 from Instituto de Salud Carlos III, State Research Agency (Spain), co-funded by the European Union. L.F. is funded by Italian Ministry of Health - Ricerca Corrente. T.S. is recipient of a research contract from the Miguel Servet Program from the Instituto de Salud Carlos III, Ref. CPII17/00027, co-funded by the European Union., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer

  • Fernández-Rozadilla, Ceres|||0000-0001-7330-4804
  • Álvarez-Barona, Miriam|||0000-0002-3843-7481
  • Quintana, Isabel
  • López-Novo, Jorge Amigo
  • Amigo, Jorge|||0000-0002-1362-2605
  • Cameselle-Teijeiro, José Manuel|||0000-0002-5516-8914
  • Roman, Eva|||0000-0001-9084-8555
  • Gonzalez, Dolors
  • Llor, Xavier|||0000-0002-6259-185X
  • Bujanda, Luis|||0000-0002-4353-9968
  • Bessa Caserras, Xavier|||0000-0003-4680-1228
  • Jover, Rodrigo
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Castells, Antoni|||0000-0001-8431-2033
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Capella, Gabriel|||0000-0002-4669-7320
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Valle, Laura|||0000-0003-0371-0844
  • Ruiz-Ponte, Clara|||0000-0002-2200-0162
Colorectal cancer (CRC) is a complex disease that can be caused by a spectrum of genetic variants ranging from low to high penetrance changes, that interact with the environment to determine which individuals will develop the disease. In this study, we sequenced 20 early-onset CRC patients to discover novel genetic variants that could be linked to the prompt disease development. Eight genes, CHAD, CHD1L, ERCC6, IGTB7, PTPN13, SPATA20, TDG and TGS1, were selected and re-sequenced in a further 304 early onset CRC patients to search for rare, high-impact variants. Although we found a recurring truncating variant in the TDG gene shared by two independent patients, the results obtained did not help consolidate any of the candidates as promising CRC predisposing genes. However, we found that potential risk alleles in our extended list of candidate variants have a tendency to appear at higher numbers in younger cases. This supports the idea that CRC onset may be oligogenic in nature and may show molecular heterogeneity. Further, larger and robust studies are thus needed to unravel the genetics behind early-onset CRC development, coupled with novel functional analyses and omic approaches that may offer complementary insight.